Gentherm
THRM
28.13
-2.06
-6.82%
Gentherm
US · THRM
#2925 by market cap
28.13
-2.06
-6.82%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.65, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
Single-engine
- Automotive is the largest reported line at 96.42% of revenue, across 2 reported segments.
- The next-largest line, Medical, is a distant second at 3.58% - a sharp slowdown here would have little to offset it.
Revenue annual, last 8 years
Latest year +2.92% YoY
Margins
- Gross margin
- 24.17%
- Operating margin
- 6.50%
- Net margin
- 1.22%
Key ratios & quality
- Enterprise valuei
- 1.51B
- Altman Z-Scorei
- 3.65
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.05B | 971.68M | 913.10M | 1.05B | 1.20B | 1.47B | 1.46B | 1.50B |
| Gross profit | 304.86M | 288.34M | 268.10M | 303.63M | 273.65M | 351.62M | 366.43M | 362.18M |
| Selling & admin expenses | 137.40M | 118.68M | 105.04M | 109.55M | 132.69M | 155.58M | 155.11M | 170.05M |
| Research & development | 79.90M | 72.48M | 68.04M | 75.21M | 85.72M | 94.36M | 88.70M | 94.76M |
| Operating profit | 87.56M | 97.18M | 95.02M | 118.86M | 55.24M | 101.69M | 122.63M | 97.37M |
| Pretax profit | 58.12M | 59.15M | 81.56M | 113.85M | 38.38M | 54.95M | 102.27M | 35.84M |
| Tax | 16.22M | 10.29M | 21.87M | 20.42M | 13.94M | 14.61M | 37.32M | 17.55M |
| Net profit | 41.90M | 48.87M | 59.69M | 93.43M | 24.44M | 40.34M | 64.95M | 18.29M |
| Basic EPS | 1 | 1 | 2 | 3 | 1 | 1 | 2 | 1 |
| Diluted EPS | 1.16 | 1.47 | 1.81 | 2.79 | 0.73 | 1.22 | 2.06 | 0.59 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 375.09M | 386.87M | 382.79M | 393.71M | 416.17M | 405.10M |
| Gross profit | 89.76M | 95.15M | 90.80M | 97.23M | 96.43M | 94.30M |
| Selling & admin expenses | 41.09M | 42.88M | 47.61M | 55.31M | 55.71M | 51.64M |
| Research & development | 22.56M | 24.43M | 23.56M | 23.95M | 24.07M | 23.47M |
| Operating profit | 26.12M | 27.84M | 19.64M | 17.98M | 16.65M | 19.20M |
| Pretax profit | 2.53M | 20.88M | 10.33M | 7.61M | 7.32M | 10.84M |
| Tax | 2.06M | 5.94M | 7.35M | 3.40M | 2.90M | 13.43M |
| Net profit | 477.00K | 14.95M | 2.99M | 4.22M | 4.42M | -2.59M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.02 | 0.49 | 0.10 | 0.14 | 0.14 | -0.08 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 443.08M | 373.86M | 643.61M | 565.85M | 683.87M | 687.56M | 684.02M | 776.95M |
| Cash & ST investments | 39.62M | 50.44M | 268.35M | 190.61M | 153.89M | 149.67M | 134.13M | 160.83M |
| Inventory | 112.54M | 118.48M | 122.40M | 159.48M | 218.25M | 205.89M | 227.36M | 252.70M |
| Total assets | 803.05M | 738.83M | 1.02B | 935.34M | 1.24B | 1.23B | 1.25B | 1.40B |
| Total current liabilities | 175.40M | 156.70M | 205.98M | 213.09M | 285.63M | 324.95M | 340.29M | 404.31M |
| Short-term debt | 3.41M | 7.09M | 8.53M | 8.17M | 9.59M | 8.32M | 7.65M | 9.72M |
| Long-term debt | 136.48M | 78.12M | 189.93M | 36.25M | 232.65M | 222.22M | 220.06M | 189.00M |
| Total liabilities | 323,348,000.00 | 254,736,000.00 | 436,508,000.00 | 281,537,000.00 | 567,027,000.00 | 589,649,000.00 | 630,609,000.00 | 676,106,000.00 |
| Total equity | 479.70M | 484.10M | 586.33M | 653.81M | 672.27M | 644.72M | 616.95M | 720.32M |
| Retained earnings | 363.97M | 413.09M | 472.78M | 566.22M | 590.66M | 624.38M | 695.80M | 714.09M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 758.82M | 785.89M | 776.95M | 826.20M | 880.01M | 927.48M |
| Cash & ST investments | 128.30M | 154.25M | 160.83M | 177.40M | 213.17M | 252.10M |
| Inventory | 248.38M | 253.25M | 252.70M | 256.97M | 244.54M | 263.49M |
| Total assets | 1.36B | 1.38B | 1.40B | 1.43B | 1.49B | 1.56B |
| Total current liabilities | 376.93M | 400.33M | 404.31M | 418.43M | 426.28M | 451.94M |
| Short-term debt | 10.06M | 10.29M | 9.72M | 9.14M | 9.07M | 8.76M |
| Long-term debt | 209.00M | 189.00M | 189.00M | 219.00M | 272.39M | 319.53M |
| Total liabilities | 661,656,000.00 | 663,387,000.00 | 676,106,000.00 | 713,824,000.00 | 770,086,000.00 | 840,981,000.00 |
| Total equity | 699.75M | 717.95M | 720.32M | 716.47M | 723.12M | 721.32M |
| Retained earnings | 696.15M | 711.10M | 714.09M | 718.30M | 722.72M | 720.13M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 118.43M | 118.80M | 110.70M | 143.08M | 14.95M | 119.27M | 109.65M | 116.79M |
| Depreciation & amortization | 50.64M | 44.25M | 41.11M | 38.78M | 44.39M | 50.95M | 52.98M | 53.38M |
| Free cash flow | 76.89M | 95.07M | 90.34M | 97.05M | -25.25M | 80.85M | 35.38M | 59.88M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -149.26M | -64.69M | -9.09M | -20.00M | 0 | -91.09M | -51.59M | -10.02M |
| Ending cash balance | 39.62M | 52.95M | 268.35M | 190.61M | 153.89M | 149.67M | 134.13M | 160.83M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 45.05M | 56.12M | 28.97M | -5.04M | 7.32M | 33.74M |
| Depreciation & amortization | 13.16M | 13.39M | 13.90M | 14.22M | 14.52M | 15.46M |
| Free cash flow | 35.75M | 46.14M | 6.35M | -10.69M | -1.49M | 25.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 0 | -- | -- | 0 |
| Ending cash balance | 128.30M | 154.25M | 160.83M | 177.40M | 213.17M | 252.10M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.11 | 7.88 | 11.27 | 15.07 | 3.69 | 6.13 | 10.30 | 2.73 |
| ROA %i | 4.97 | 4.90 | 6.82 | 9.54 | 2.25 | 3.26 | 5.23 | 1.38 |
| ROIC %i | 6.90 | 6.84 | 9.18 | 12.53 | 3.29 | 5.59 | 8.42 | 3.09 |
| 5-year avg ROE %i | 17.59 | 14.29 | 10.90 | 10.28 | 9.63 | 9.23 | 9.27 | 7.58 |
| EBIT margin %i | 6.07 | 6.58 | 9.43 | 11.15 | 3.54 | 4.74 | 8.07 | 3.31 |
| FCF / sales %i | 7.41 | 9.78 | 9.89 | 9.28 | -- | 5.50 | 2.43 | 4.00 |
| Current ratioi | 2.53 | 2.39 | 3.12 | 2.66 | 2.39 | 2.12 | 2.01 | 1.92 |
| Quick ratioi | 1.40 | 1.51 | 2.47 | 1.86 | 1.52 | 1.36 | 1.25 | 1.19 |
| Debt / assetsi | 17.42 | 12.45 | 21.77 | 6.86 | 21.20 | 19.99 | 21.22 | 17.68 |
| LT debt / equityi | 28.45 | 17.53 | 36.53 | 8.57 | 37.66 | 36.98 | 41.68 | 32.92 |
| Interest coveragei | 12.76 | 13.42 | 18.89 | 42.28 | 9.94 | 4.75 | 7.68 | 3.59 |
| Revenue CAGR (3Y) %i | 6.98 | 1.93 | -2.79 | -0.07 | 7.43 | 17.18 | 11.65 | 7.55 |
| Net income CAGR (3Y) %i | -23.99 | -13.91 | 19.22 | 30.65 | -20.62 | -12.24 | -11.42 | -9.22 |
| FCF CAGR (3Y) %i | 16.03 | 31.21 | -- | 8.07 | -- | -3.63 | -28.57 | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 4.72 | 4.44 | 2.73 | 3.32 | 3.74 | 1.26 |
| ROA %i | 2.43 | 2.29 | 1.38 | 1.63 | 1.86 | 0.61 |
| ROIC %i | 4.65 | 4.39 | 3.09 | 3.10 | 3.36 | 1.62 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 5.21 | 5.17 | 3.31 | 3.53 | 3.69 | 3.05 |
| FCF / sales %i | 3.23 | 4.55 | 4.00 | 5.04 | 2.55 | 1.23 |
| Current ratioi | 2.01 | 1.96 | 1.92 | 1.97 | 2.06 | 2.05 |
| Quick ratioi | 1.22 | 1.20 | 1.19 | 1.25 | 1.37 | 1.35 |
| Debt / assetsi | 19.85 | 18.02 | 17.68 | 19.12 | 21.77 | 23.73 |
| LT debt / equityi | 37.18 | 33.24 | 32.92 | 36.89 | 43.70 | 50.19 |
| Interest coveragei | 4.84 | 5.32 | 3.59 | 4.21 | 4.80 | 3.85 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Automotive96.42%
Medical3.58%
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Gentherm discussion 0 comments